Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers

13 Mar 2024

Abstract excerpt

Blood-based liquid biopsy is increasingly used in clinical care of patients with cancer, and fraction of tumor-derived DNA in circulation (tumor fraction; TFx) has demonstrated clinical validity across multiple cancer types. To determine TFx, shallow whole-genome sequencing of cell-free DNA (cfDNA) can be performed from a single blood sample, using an established computational pipeline (ichorCNA), without prior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38490303
DOI: 10.1016/j.jmoldx.2024.01.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced CancersPMID 38490303Read ↗

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Semantic proximity Read ↗

Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sampleSemantic proximity Read ↗

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumorsSemantic proximity Read ↗

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care NetworkSemantic proximity Read ↗

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.Semantic proximity Read ↗

Challenges in Using ctDNA to Achieve Early Detection of CancerSemantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Liquid biopsies across the cancer care continuum.Semantic proximity Read ↗

Detection of Circulating Tumor DNA in Plasma Using Targeted Sequencing.Semantic proximity Read ↗

Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity Read ↗

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

Evaluation of cell-free DNA approaches for multi-cancer early detectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.